<DOC>
	<DOCNO>NCT00003158</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness radiation therapy chemotherapy consist carboplatin , etoposide paclitaxel treat patient newly diagnose stage III non-small cell lung cancer .</brief_summary>
	<brief_title>S9712 : Radiation Therapy Combination Chemotherapy Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess survival failure-free survival poor risk patient stage IIIA IIIB non-small cell lung carcinoma treat concurrent radiation , carboplatin , etoposide follow consolidation paclitaxel . II . Evaluate response toxicity associate regimen group poor risk patient . OUTLINE : This nonrandomized study . Chemotherapy cycle 1 start day 1 concurrent initiation radiotherapy . Chemotherapy give prior radiotherapy day treatment give . Cycle 2 begin day 29 . Carboplatin administer 15 minute IV infusion day 1 , 3 , 29 , 31 . Etoposide ( VP-16 ) administer carboplatin 30 minute IV infusion day 1-4 , 29-32 . Radiation therapy begin within 24 hour day 1 , cycle 1 chemotherapy . The primary tumor , adjacent mediastinum , target lymph node administer radiotherapy daily 5 day week 6.5 week . After 2 cycle chemotherapy chest radiotherapy , patient stable disease , partial response , complete response receive 3 cycle paclitaxel . Paclitaxel administer 3 hour IV infusion start 4 week completion chemotherapy radiotherapy repeat every 3-4 week ( approximately day 71 , 92 , 103 ) total 3 cycle . Patients follow every month first year , every 3 month second year , every 6 month third year , annually thereafter treatment . After treatment , patient follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : There 80 patient accrue study 16 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose single primary bronchogenic nonsmall cell lung cancer ( NSCLC ) Stage IIIA ( T12 N2 M0 ; T3 N02 M0 ) IIIB ( T4 N3 M0 , exclude malignant pleural effusion ) Following NSCLC cellular type eligible : adenocarcinoma large cell carcinoma squamous cell carcinoma unspecified Histology cytology involve mediastinal supraclavicular node sufficient diagnosis separate primary lesion lung parenchyma clearly evident radiograph Radiographic evidence mediastinal lymph node least 1.5 cm large diameter sufficient stage N2 N3 If large mediastinal node le 1.5 cm diameter basis stage III disease , least one node proven positive cytologically histologically No bronchioloalveolar carcinoma stage IIIB tumor involve superior sulcus Patients must meet least one follow condition : FEV1 le 2 liter predict FEV1 contralateral lung great 800 mL base quantitative split function test Creatinine clearance le 50 mL/min Significant clinical hearing loss unwilling accept potential worsening due cisplatin Controlled congestive heart failure , opinion investigator , may become decompensated due excessive hydration prior cisplatin administration SWOG performance status 2 either albumin less 0.85 time upper limit normal weight loss great 10 % due tumor Measurable evaluable disease Patients pleural effusion eligible : pleural fluid must transudate negative cytology present mediastinoscopy exploratory thoracotomy pleural fluid either transudate exudate negative cytology present exploratory stag thoracotomy case , pleural effusion present CT scan decubitus chest xray , deem small tap either CT ultrasound guidance PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,200/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal SGOT great 1.5 time upper limit normal Renal : Creatinine clearance least 20 mL/min Cardiovascular : No unstable congestive heart failure No active angina No unstable cardiac arrhythmia Pulmonary : FEV1 least 1.0 liter Also See Disease Characteristics Other : No uncontrolled peptic ulcer disease No active infection No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free 5 year Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiation lung cancer Surgery : No prior surgery lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>